PNC Financial Services Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

PNC Financial Services Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-97	Closed	-$7K	–	4722
2022 Q2	$7K	Sell	97 -8,449	-99%	-$375K	﹤0.01%	3924
2022 Q1	$230K	Buy	8,546 +888	+12%	+$29.8K	﹤0.01%	2161
2021 Q4	$364K	Sell	7,658 -28	-0.4%	-$1.25K	﹤0.01%	1891
2021 Q3	$511K	Buy	7,686 +84	+1%	+$5.98K	﹤0.01%	1593
2021 Q2	$594K	Buy	7,602 +2,482	+48%	+$183K	﹤0.01%	1494
2021 Q1	$484K	Buy	5,120 +460	+10%	+$54.7K	﹤0.01%	1588
2020 Q4	$568K	Buy	4,660 +620	+15%	+$67.9K	﹤0.01%	1403
2020 Q3	$352K	Buy	4,040 +860	+27%	+$59.9K	﹤0.01%	1578
2020 Q2	$206K	Buy	3,180 +640	+25%	+$36.9K	﹤0.01%	1910
2020 Q1	$114K	Buy	+2,540	New	+$135K	﹤0.01%	2146

PNC Financial Services Group's TPTX Position: Q3 2022 in Review

PNC Financial Services Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 97 shares — an estimated $7K sold.

PNC Financial Services Group first reported a position in TPTX in Q1 2020 and held it in 10 quarters. The position peaked at $594K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

PNC Financial Services Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
PNC Financial Services Group sold 97 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $7K.
PNC Financial Services Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 10 quarters.
PNC Financial Services Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $594K in Q2 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on PNC Financial Services Group's 13F filing for Q3 2022, filed 10 Nov 2022.